Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
<p>Abstract</p> <p>Background</p> <p>Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-07-01
|
| Series: | BMC Infectious Diseases |
| Online Access: | http://www.biomedcentral.com/1471-2334/8/102 |
| _version_ | 1818542484706295808 |
|---|---|
| author | Fleischhack Gudrun Bode Udo Wiszniewsky Gertrud Ammann Roland A Simon Arne Besuden Mette M |
| author_facet | Fleischhack Gudrun Bode Udo Wiszniewsky Gertrud Ammann Roland A Simon Arne Besuden Mette M |
| author_sort | Fleischhack Gudrun |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients with a long term central venous access device (CVAD, Port- or/Broviac-/Hickman-catheter type).</p> <p>Methods</p> <p>In a single center prospective 48-months cohort study we compared all patients receiving anticancer chemotherapy from April 2003 to March 2005 (group 1, heparin lock with 200 IU/ml sterile normal saline 0.9%; Canusal<sup>® </sup>Wockhardt UK Ltd, Wrexham, Wales) and all patients from April 2005 to March 2007 (group 2; taurolidine 1.35%/Sodium Citrate 4%; TauroLock™, Tauropharm, Waldbüttelbrunn, Germany).</p> <p>Results</p> <p>In group 1 (heparin), 90 patients had 98 CVAD in use during the surveillance period. 14 of 30 (47%) BSI were 'primary Gram positive BSI due to CoNS (n = 4) or MRSE (n = 10)' [incidence density (ID); 2.30 per 1000 inpatient CVAD-utilization days].</p> <p>In group 2 (TauroLock™), 89 patients had 95 CVAD in use during the surveillance period. 3 of 25 (12%) BSI were caused by CoNS. (ID, 0.45). The difference in the ID between the two groups was statistically significant (P = 0.004).</p> <p>Conclusion</p> <p>The use of Taurolidin/Citrate (TauroLock™) significantly reduced the number and incidence density of primary catheter-associated BSI due to CoNS and MRSE in pediatric cancer patients.</p> |
| first_indexed | 2024-12-11T22:22:41Z |
| format | Article |
| id | doaj.art-c0357c9684704dba956f695f3db0fc3f |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-11T22:22:41Z |
| publishDate | 2008-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-c0357c9684704dba956f695f3db0fc3f2022-12-22T00:48:24ZengBMCBMC Infectious Diseases1471-23342008-07-018110210.1186/1471-2334-8-102Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patientsFleischhack GudrunBode UdoWiszniewsky GertrudAmmann Roland ASimon ArneBesuden Mette M<p>Abstract</p> <p>Background</p> <p>Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients with a long term central venous access device (CVAD, Port- or/Broviac-/Hickman-catheter type).</p> <p>Methods</p> <p>In a single center prospective 48-months cohort study we compared all patients receiving anticancer chemotherapy from April 2003 to March 2005 (group 1, heparin lock with 200 IU/ml sterile normal saline 0.9%; Canusal<sup>® </sup>Wockhardt UK Ltd, Wrexham, Wales) and all patients from April 2005 to March 2007 (group 2; taurolidine 1.35%/Sodium Citrate 4%; TauroLock™, Tauropharm, Waldbüttelbrunn, Germany).</p> <p>Results</p> <p>In group 1 (heparin), 90 patients had 98 CVAD in use during the surveillance period. 14 of 30 (47%) BSI were 'primary Gram positive BSI due to CoNS (n = 4) or MRSE (n = 10)' [incidence density (ID); 2.30 per 1000 inpatient CVAD-utilization days].</p> <p>In group 2 (TauroLock™), 89 patients had 95 CVAD in use during the surveillance period. 3 of 25 (12%) BSI were caused by CoNS. (ID, 0.45). The difference in the ID between the two groups was statistically significant (P = 0.004).</p> <p>Conclusion</p> <p>The use of Taurolidin/Citrate (TauroLock™) significantly reduced the number and incidence density of primary catheter-associated BSI due to CoNS and MRSE in pediatric cancer patients.</p>http://www.biomedcentral.com/1471-2334/8/102 |
| spellingShingle | Fleischhack Gudrun Bode Udo Wiszniewsky Gertrud Ammann Roland A Simon Arne Besuden Mette M Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients BMC Infectious Diseases |
| title | Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients |
| title_full | Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients |
| title_fullStr | Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients |
| title_full_unstemmed | Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients |
| title_short | Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients |
| title_sort | taurolidine citrate lock solution taurolock significantly reduces cvad associated grampositive infections in pediatric cancer patients |
| url | http://www.biomedcentral.com/1471-2334/8/102 |
| work_keys_str_mv | AT fleischhackgudrun taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients AT bodeudo taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients AT wiszniewskygertrud taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients AT ammannrolanda taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients AT simonarne taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients AT besudenmettem taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients |